A Phase 1/1b Dose-Escalation Trial Evaluating Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Patients With Relapsed/Refractory T-Cell Lymphoma
Hematological Oncology - United Kingdom
doi 10.1002/hon.11_2632
Full Text
Open PDFAbstract
Available in full text
Date
June 1, 2019
Authors
Publisher
Wiley